DK1633883T3 - Fremgangsmåde til analyse af LKB1-phosphoryleringsaktivitet - Google Patents

Fremgangsmåde til analyse af LKB1-phosphoryleringsaktivitet

Info

Publication number
DK1633883T3
DK1633883T3 DK04742944T DK04742944T DK1633883T3 DK 1633883 T3 DK1633883 T3 DK 1633883T3 DK 04742944 T DK04742944 T DK 04742944T DK 04742944 T DK04742944 T DK 04742944T DK 1633883 T3 DK1633883 T3 DK 1633883T3
Authority
DK
Denmark
Prior art keywords
ampk
lkb1
analyzing
substrate kinase
phosphorylation
Prior art date
Application number
DK04742944T
Other languages
English (en)
Inventor
David Carling
Angela Woods
Fiona Leiper
Marian Carlson
Seung Hong
Original Assignee
Medical Res Council
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0329866A external-priority patent/GB2402938B/en
Application filed by Medical Res Council, Univ Columbia filed Critical Medical Res Council
Application granted granted Critical
Publication of DK1633883T3 publication Critical patent/DK1633883T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45Transferases (2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Obesity (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
DK04742944T 2003-06-17 2004-06-17 Fremgangsmåde til analyse af LKB1-phosphoryleringsaktivitet DK1633883T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47910003P 2003-06-17 2003-06-17
GB0329866A GB2402938B (en) 2003-06-17 2003-12-23 Kinase assay
PCT/GB2004/002584 WO2004113562A1 (en) 2003-06-17 2004-06-17 Method for assaying lkb1 phosphorylation activity

Publications (1)

Publication Number Publication Date
DK1633883T3 true DK1633883T3 (da) 2009-01-26

Family

ID=33542697

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04742944T DK1633883T3 (da) 2003-06-17 2004-06-17 Fremgangsmåde til analyse af LKB1-phosphoryleringsaktivitet

Country Status (7)

Country Link
EP (1) EP1633883B1 (da)
JP (1) JP4651617B2 (da)
AT (1) ATE408023T1 (da)
DE (1) DE602004016503D1 (da)
DK (1) DK1633883T3 (da)
ES (1) ES2313029T3 (da)
WO (1) WO2004113562A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004013160T2 (de) * 2003-07-17 2009-07-02 University Of Dundee, Dundee Verfahren zur anwendung eines an lkb1/strad/mo25-komplexes
WO2005049849A2 (en) 2003-11-14 2005-06-02 Integrated Dna Technologies, Inc. Fluorescence quenching azo dyes, their methods of preparation and use
JP5039565B2 (ja) * 2005-02-16 2012-10-03 エムディー バイオアルファ カンパニー リミテッド 肥満、糖尿病、メタボリックシンドローム、神経変性疾患およびミトコンドリア機能不全関連疾患に伴う疾患を治療または予防するための医薬組成物
CA2601554A1 (en) * 2005-05-20 2006-11-30 Integrated Dna Technologies, Inc. Compounds and methods for labeling oligonucleotides
US9506057B2 (en) 2010-03-26 2016-11-29 Integrated Dna Technologies, Inc. Modifications for antisense compounds
EP2553123B1 (en) 2010-03-26 2016-08-24 Integrated DNA Technologies, Inc. Methods for enhancing nucleic acid hybridization
EP2614149B1 (en) 2010-09-07 2015-04-08 Integrated Dna Technologies, Inc. Modifications for antisense compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999028459A1 (fr) * 1997-11-27 1999-06-10 Chugai Research Institute For Molecular Medicine, Inc. Technique d'examen, reactif pour examen et medicament relatif a des affections provoquees par des modifications survenues dans le gene lkb1
AU2001269785A1 (en) * 2000-06-09 2001-12-17 Brigham Young University Method of treatment of obesity and paralyzed muscle and ergogenic aids

Also Published As

Publication number Publication date
DE602004016503D1 (de) 2008-10-23
JP4651617B2 (ja) 2011-03-16
EP1633883B1 (en) 2008-09-10
ES2313029T3 (es) 2009-03-01
WO2004113562A1 (en) 2004-12-29
EP1633883A1 (en) 2006-03-15
ATE408023T1 (de) 2008-09-15
JP2007520199A (ja) 2007-07-26

Similar Documents

Publication Publication Date Title
Moura et al. α2‐Adrenoceptor subtypes involved in the regulation of catecholamine release from the adrenal medulla of mice
WO2007120480A3 (en) Systems and methods for predicting effectiveness in the treatment of psychiatric disorders, including depression
WO2005034869A3 (en) Compounds and compositions as protein kinase inhibitors
Hernández et al. Changes in erythrocyte enzymes in humans long-term exposed to pesticides: influence of several markers of individual susceptibility
PT991628E (pt) Compostos de quinolina e quinoxalina que inibem o factor de crescimento derivado das plaquetas e/ou a tirosina cinase p561ck
ATE474569T1 (de) Verwendung von sphingosin-1-phosphat (s1p) rezeptor-agonisten zur behandlung von degenerativen gehirnerkrankungen
WO2007030693A3 (en) Methods for promoting stem cell proliferation and survival
ATE492228T1 (de) Knochenplatte
WO2002000918A3 (de) Biosensor und herstellverfahren dafür
NZ512096A (en) Quinoline and quinoxaline compounds as PDGF-receptor and/or LCK tyrosine kinase inhibitors
WO2006089233A3 (en) Methods and systems for diagnosis, prognosis and selection of treatment of leukemia
WO2003023573A3 (en) Patient classification
EP1607100A4 (en) MEDICAMENT WITH AN INTERLEUKIN-6 ANTAGONIST FOR BACK-MARGIN INJURIES
WO2008057458A3 (en) Antagonists of pcsk9
WO2004072265A3 (en) Methods for monitoring drug activities in vivo
WO2007070640A3 (en) Use of roma for characterizing genomic rearrangements
ATE408023T1 (de) Verfahren zum testen der lkb1- phosphorylierungsaktivität
WO2003054182A3 (en) Production of butyrylcholinesterases in transgenic mammals
BRPI0512422A (pt) compostos e composições como inobidores da proteìna quinase
MX2008001605A (es) Compuestos y composiciones de tiazol-2-il amino 5-substituido como inhibidores de cinasa proteica.
BRPI0516950A (pt) 4-(metila cìclica condensada)-imidazol-2-tionas atuando como agonistas adrenérgicos alfa2
NO20055025L (no) Multiplex screening for lysosomale lagringsforstyrrelser (LSD)
WO2006060265A3 (en) Methods and systems for prognosis and treatment of solid tumors
WO2006001954A3 (en) Methods for promoting the formation of platelets and for treating blood and bone marrow disorders
DK1756571T3 (da) Fremgangsmåde i realtid til detektering af akut inflammatoriske tilstande